Switzerland-based Lonza has expanded its GMP solutions for cell and gene therapy with the launch of TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium.  

Cytokines represent a critical component in cell therapy manufacturing, supporting the expansion and maintenance of living cells. According to Lonza, its TheraPEAK AmpliCell Cytokines enable the reliable expansion, activation, and differentiation of immune cells.

“Produced in a mammalian expression system and engineered for high biological activity, these cytokines feature proper folding and glycosylation, delivering native-like structure and function that bacterial systems cannot match. This ensures superior biological relevance, batch-to-batch consistency, and greater predictability in sensitive and translational applications, both in research and GMP set-ups,” it explained.

TheraPEAK 293-GT Medium is a chemically defined, animal–origin–free system optimised for adeno-associated virus (AAV) production in suspension HEK293 cells, providing a reliable, scalable option for advancing gene therapy programmes.

“Unlike off-the-shelf viral production kits that may lack flexibility, the 293-GT System (growth medium plus supplement) is a drop-in-ready solution engineered to integrate seamlessly with existing workflows. The media is compatible with commercially available transfection reagents and AAV enhancers, delivers strong AAV titers, and supports high full-to-empty capsid ratios,” the company noted.

TheraPEAK Products have been used in FDA-approved therapies and more than 130 clinical trials across the globe. The newly-added solutions provide researchers and manufacturers with high-performance, scalable, and regulatory-ready solutions that streamline cell and gene therapy workflows from discovery through clinical development.

Mike Goetter, Head of Bioscience, Specialised Modalities, Lonza, said, "The introduction of AmpliCell Cytokines and the 293-GT Medium to our TheraPEAK Range greatly enhances our offering for cell and gene therapy customers, providing them with reliable solutions to support their drug development efforts."